Alembic lands generic Haldol approval, but the US market is tiny
Final USFDA clearance for Haloperidol Tablets adds to a 240-product pipeline. The market it addresses is less than 3% of Alembic's revenue.
— 9 earlier stories on Alembic Pharmaceuticals Ltd. →What's new
- USFDA granted final approval for Alembic's Haloperidol Tablets, a generic of Haldol.
- The approved product addresses a US market worth about $27 million.
- It is the 240th ANDA in Alembic's approved pipeline.
Why this matters
Alembic's annual revenue is ₹7,345 crore. The $27 million Haloperidol market, if fully captured, would represent less than 3% of that total. The approval keeps the pipeline machine running but doesn't change the company's earnings trajectory.
What we're watching
- The timing and scale of the product launch in the US.
- Which ANDAs in the 240-product pipeline carry real commercial weight.
- How Alembic's US base business performs against this low-bar addition.
The full read
Alembic Pharmaceuticals has received final USFDA approval to sell Haloperidol Tablets, a generic of Haldol. The product addresses a US market of $27 million (~₹224 crore). For a company with ₹7,345 crore in annual revenue, that's a potential contribution of less than 3%. This is Alembic's 240th approved ANDA. The number signals pipeline activity. Not a near-term financial boost. The approval is a routine pipeline addition, not an event that alters the company's earnings profile or valuation.
Questions answered
- Why is this approval considered routine?
- The US market for generic Haloperidol is only $27 million, which is less than 3% of Alembic's ₹7,345 crore in annual revenue. The approval adds one more product to a large pipeline without moving the earnings needle.
- How significant is a 240th ANDA approval?
- The number itself shows depth in the US generic filing pipeline. However, the commercial impact of any single ANDA depends on the market size it addresses, and this particular market is small.
- What is the product's origin?
- Alembic's Haloperidol Tablets are a generic version of Haldol, a drug used primarily in psychiatric care.
- Does this approval affect Alembic's India business?
- No. The approval is for the US market. Alembic's revenue breakdown between India and other geographies is not detailed in this filing.
Alembic Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on APLLTD →- 5 Jun 2026 · 10:53 AM IST Alembic lands generic Haldol approval, but the US market is tiny
- today Alembic gets USFDA OK for Prucalopride, but $100M market faces competition
- 10d ago Alembic's partner lands tentative OK for $1.4B cancer drug
- 15d ago Alembic gets USFDA warning letter over ICF; facility unimpacted
- 39d ago Alembic eyes $259M cancer market with tentative US nod for Binimetinib